{"id":6885,"date":"2026-04-29T11:01:56","date_gmt":"2026-04-29T09:01:56","guid":{"rendered":"https:\/\/hemerapharma.com\/?p=6885"},"modified":"2026-04-30T11:22:54","modified_gmt":"2026-04-30T09:22:54","slug":"hemera-on-le-scienze-scientific-america-edition","status":"publish","type":"post","link":"https:\/\/hemerapharma.com\/en\/hemera-on-le-scienze-scientific-america-edition\/","title":{"rendered":"Le Scienze publishes a feature on Hemera and REMaST\u00ae in regenerative medicine for the nervous system"},"content":{"rendered":"

Hemera is featured in the article published in Le Scienze <\/em>(May issue), the Italian edition of Scientific American<\/a>, one of the oldest and most authoritative international scientific magazines, focusing on the development of the REMaST\u00ae<\/a> platform for spinal cord injury and its transition toward clinical development.<\/p>\n

The article traces the scientific trajectory of the program, from the study of regenerative macrophages to the development of an advanced therapeutic approach based on reprogrammed autologous cells.<\/p>\n

Regenerative macrophages and lesion microenvironment reprogramming<\/strong><\/h5>\n

REMaST\u00ae is based on the use of reprogrammed autologous macrophages<\/strong> to modulate the lesion microenvironment and influence the biological processes that limit central nervous system regeneration.<\/p>\n

As reported in the article, engineered macrophages act across multiple levels of tissue damage, contributing to the reorganization of the lesion microenvironment and supporting neural tissue repair processes, highlighting the multifactorial nature of the approach.<\/em><\/p>\n

Hemera today: from preclinical validation to clinical transition<\/strong><\/h5>\n

\u00a0<\/strong>A key focus of the feature is the complexity of the transition from preclinical development to first-in-human<\/em> studies, one of the most critical bottlenecks in advanced therapy development.<\/p>\n

REMaST\u00ae is currently in this advanced translational phase, moving from preclinical research toward clinical developmen<\/strong>t with the goal of initiating first-in-human<\/em> trials.<\/p>\n

As highlighted by Ilaria Decimo<\/a>, R&D Director and co-founder of Hemera<\/strong>:<\/p>\n

\u201cIt is not only about translating data from preclinical to clinical stages, but about building an integrated system in which biology, manufacturing, and regulatory strategy advance together from the earliest phases.\u201d<\/p><\/blockquote>\n

In the context of ATMPs (Advanced Therapy Medicinal Products)<\/a>, for which REMaST\u00ae has held certification since 2022, this phase requires early integration between:<\/p>\n